NASHVILLE, Tenn. / Feb 09, 2023 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conferences:
March 7, 2023 at 10:25 am EST at the 2023 Raymond James & Associates 44th Annual Institutional Investors Conference at JW Marriott Grande Lakes in Orlando, FL.
March 8, 2023 at 9:50 am EST at the 2023 Cowen and Company 43rd Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA.
March 14, 2023 at 11:20 am EDT at the Oppenheimer 33rd Annual Virtual Healthcare Conference.
A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.
Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.
All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
| Last Trade: | US$387.98 |
| Daily Change: | -9.77 -2.46 |
| Daily Volume: | 1,802,296 |
| Market Cap: | US$100.130B |
July 23, 2024 April 26, 2024 April 03, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
